DSM-5 Personality Disorders in Adults with Autism

Rationale: Self-report measures are frequently used for research and clinical assessments of adults with autism spectrum disorder (ASD). However, there has been little research examining agreement between self-report and informant-report in this population. Reliable self-report measures are essential for conducting research with and providing high quality clinical services for adults with autism spectrum disorder.

Objective: This study aims to examine the usefulness of self-report of DSM-5-TR PD traits in adults with ASD compared to informant-reports by administering the self-report screening measure of the Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).

Study Overview

• Status: Recruiting
• Conditions: Autism Spectrum Disorder
• Intervention / Treatment: Other: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).

• Study Type: Observational
• Enrollment (Estimated): 102

Contacts and Locations

Study Locations

• Netherlands
  • Rotterdam, Netherlands
    • Recruiting
    • Sarr - Parnassia Groep Antes
    • Contact: Thomas Kramer, MSc; Phone Number: 088 358 1616; Email: t.kramer@anteszorg.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult males and females (age ≥ 18 years), clinically diagnosed with ASD by a psychologist or a psychiatrist, without intellectual disability, and their informants. ASD participants will be recruited from Sarr Autism Rotterdam, the Netherlands, specialized in psychodiagnostic assessment and treatment for children, adolescents, and adults with ASD. Sarr is part of Parnassia Groep, multisite mental health institute in the Netherlands.

Description

Inclusion criteria Inclusion criteria for ASD participants: (1) primary diagnosis of ASD according to the DSM-5-TR, (2) age 18+ years, (3) no intellectual disability, and (4) at least having completed a primary and secondary education.

Inclusion criteria for informants:

Participants were asked to identify individuals who knew them well and were capable of providing accurate descriptions of their personality traits, preferably informants that cohabited with the participants. When cohabitants were unavailable, participants were asked to identify "the person who knows you best." Additionally, eligibility of informants for inclusion required that, historically, the informant and the participant talked at least monthly and interacted face-to-face at least yearly.

Exclusion criteria Exclusion criteria for ASD participants: (1) no ASD diagnosis, (2) current substance abuse, (3) psychotic disorders, (4) schizophrenia, (5) eating disorder, (6), mental retardation (IQ<80), (7) suicidal ideations and (8) age <18 years.

Exclusion criteria for informants: (1) age <18 years, (2) intellectual disability, and (3) not being able to state and/or recognize psychological and problematic functioning of their participating relative with ASD.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
1; Adults with autism spectrum disorder	Other: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).; Screening questionnaire
2; The relative of the adult with autism spectrum disorder	Other: Structured Clinical Interview for DSM-5 Screening Personality Questionnaire (SCID-5-SPQ).; Screening questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Score SCID-5-PD	The main study parameters are the item scores on the SCID-5-PD.	1 day

Collaborators and Investigators

• Sponsor: Parnassia Groep

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2024
• Primary Completion (Estimated): September 30, 2025
• Study Completion (Estimated): September 30, 2025

Study Registration Dates

• First Submitted: December 5, 2024
• First Submitted That Met QC Criteria: December 5, 2024
• First Posted (Estimated): December 10, 2024

Study Record Updates

• Last Update Posted (Estimated): December 10, 2024
• Last Update Submitted That Met QC Criteria: December 5, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Keywords: Autism; Personality disorder
• Additional Relevant MeSH Terms: Mental Disorders; Neurodevelopmental Disorders; Child Development Disorders, Pervasive; Autism Spectrum Disorder; Autistic Disorder; Personality Disorders
• Other Study ID Numbers: 2022.56

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No